Shares of Doximity fell 5.1% in pre-open trading to $19.82 as investors responded to fresh analyst activity and lingering doubts stemming from the company’s fiscal reporting. The latest broker notes, issued on June 25, added to downward momentum that began after the company’s fiscal fourth-quarter 2026 update.
Analyst actions
On June 25, JPMorgan analyst Alexei Gogolev maintained a Neutral rating on the stock but trimmed his price objective to $26 from $28. On the same day, Leerink Partners analyst Michael Cherny lowered his target to $25 from $31 while keeping an Outperform rating. Those moves were highlighted by market participants as continuing headwinds for sentiment heading into today’s session.
Earnings and guidance context
Doximity’s fiscal Q4 2026 results, released on May 13, produced a slight earnings-per-share miss versus consensus and set fiscal 2027 revenue guidance in a range of $664 million to $676 million. That guidance sits meaningfully below the Street’s approximate forecast of $699 million. The combination of a marginal EPS shortfall and conservative forward revenue targets has prompted several firms to reassess valuations and revise their price targets downward.
Follow-up analyst moves and concerns
Following the earnings report, firms including Barclays, Truist, Needham, Mizuho and BMO Capital reduced their targets. Analysts who cut estimates cited a deterioration in revenue-growth visibility, the pressure of higher AI compute costs on margins, and the April 2026 departure of Doximity’s chief financial officer as factors that together intensified investor caution. Truist analyst Jailendra Singh notably reduced his price target from $29 to $19 while retaining a Hold rating.
Market backdrop and competitive dynamic
The broader U.S. equity market offered little to explain Doximity’s move. The S&P 500 was essentially flat, the Dow Jones Industrial Average was marginally lower, and the Nasdaq Composite was down about 0.2% - indicating that the selloff was driven primarily by company-specific developments rather than broad market weakness. Market commentary has also pointed to competitors such as Veeva Systems and other healthcare-technology firms as potential beneficiaries if pharmaceutical advertising budgets shift away from Doximity.
Technical and sentiment picture
Taken together, below-consensus forward guidance, a leadership transition in finance, escalating AI-related expenses and a steady cadence of target reductions have left the shares in an extended downtrend. The stock is trading near its 52-week low of $17.15 and has pulled back substantially from its 52-week high of $76.51. Absent clear evidence that Doximity’s AI-powered workflow tools are driving sustained revenue acceleration, analyst and investor sentiment appears likely to remain pressured.
Summary
Doximity’s pre-market decline reflects renewed selling linked to analyst downgrades and target cuts following a Q4 fiscal 2026 report that missed EPS expectations slightly and issued fiscal 2027 revenue guidance well below consensus. Concerns focused on slowing revenue visibility, higher AI compute costs, and the April 2026 CFO departure. The broader market’s muted performance suggests the weakness is company-specific, while competitors in healthcare technology are seen as potential beneficiaries of any reallocation of advertising spend.